HC Wainwright Issues Positive Outlook for AARD Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Investment analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for shares of Aardvark Therapeutics in a research note issued to investors on Monday, October 19th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.55) per share for the quarter, up from their previous estimate of ($0.94). HC Wainwright has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.69) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.74) EPS.

Several other research firms also recently commented on AARD. BTIG Research reissued a “neutral” rating on shares of Aardvark Therapeutics in a research note on Monday, October 12th. Wall Street Zen raised shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. UBS Group set a $4.00 target price on shares of Aardvark Therapeutics in a report on Monday. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a report on Thursday, September 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Aardvark Therapeutics presently has an average rating of “Hold” and an average target price of $11.89.

Aardvark Therapeutics Price Performance

Shares of NASDAQ:AARD opened at $3.90 on Wednesday. Aardvark Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.60. The firm has a market capitalization of $85.33 million, a PE ratio of -1.21 and a beta of 3.80. The business’s 50 day moving average price is $5.45 and its 200-day moving average price is $5.29.

Aardvark Therapeutics (NASDAQ:AARD) last announced its earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.21.

Institutional Investors Weigh In On Aardvark Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP acquired a new position in Aardvark Therapeutics during the second quarter worth $138,000. J. Goldman & Co LP acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth $233,000. Ieq Capital LLC acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth $221,000. BlackRock Inc. acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth $1,077,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Aardvark Therapeutics during the 1st quarter worth $267,000.

Insider Buying and Selling at Aardvark Therapeutics

In other news, insider Nelson Sun sold 62,000 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the sale, the insider directly owned 35,475 shares in the company, valued at $183,760.50. This represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 17.80% of the stock is currently owned by corporate insiders.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.